Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 9 January 2021

Situation Report No. 210 - Kingdom of Bahrain

10th of January, 2021



	Glo	bal	Eastern Mediterranean Region		
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths	
Total	87,589,206	1,906,606	5,124,000	124,486	
New	2,376,339 in 3 days	43,839 in 3 days	79,353 in 3 days	1,157 in 3 days	

Kingdom of Bahrain

	Confirmed Cases Recovered Cases		Deaths	Active Cases	Critical Cases	PCR Tests
Total	95,317	92,113	355	2,849	12	2,463,161
New	1,033 in 3 days	682 in 3 days	2 in 3 days	-	-	34,945 in 3 days

HIGHLIGHTS

The mortality were a 90 year old male Bahraini Citizens and 83 year old Female Bahraini Citizens.
Increasing numbers of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 9 January 2021 is 84,157.
Industry, Commerce and Tourism Ministry shutdown 23 outlets that violated the public health precautionary measures to combat COVID-19. And, 74 defendants received court verdicts for violating COVID-19 safety rules.
Fifty positive cases of COVID-19 were reported from 14 household bias tweek.
Security and awareness plans were recently established by the Capital Police Directorate to curtail COVID-19 spread.
WHO: New research helps to increase understanding of the impact of COVID-19 pandemic; see link below.
WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
WHO: Second Colon 2000 Chain System(COVID-19) catalogue; see link below.
WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-COV-2 infection using rapidimmun oassay see link below.
WHO: Sinter user framework for the allocation and prioritization of COVID-19 variationation; see link below.
WHO: Sate Subar Stanework on COVID-19 variationation; see link below.
WHO: Sate states framework for the allocation and prioritization of COVID-19 variationation; see link below.
WHO: Sate states framework for the allocation and prioritization of COVID-19 variationation; see link below.
WHO: Sate states framework for the allocation and prioritization of COVID-19 variationation; see link below.
WHO: Sate states framework for the allocation and prioritization of COVID-19 variationation; see link below.
WHO: Sate states actionates states the below.
WHO: Sate states framework for the allocation state the value state states work; see link below.
WHO: Sate states actionation; see link below.
WHO: Sate states states acomment state below.
WH

WHO Living Guideline: The rapeutics and COVID-19; see link below.
WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
WHO: Livinene to recommendations: COVID-19 militation in the aviation sector; see link below.
WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crise; see link below.

below WH0: COVID-19 vaccine introduction and deployment costing tool; see link below. WH0: Energency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unbinding; see link below. WH0: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below. WH0: COVIA Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.

see link below. • WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below

WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link


WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
WHO: Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link

IMPORTANT LINKS

Daily COVID-19 updates on MoH website:
ttps://www.moh.gov.bh/
WHO's COVID-19 weekly situation reports:
ttps://www.who.int/docs/default-source/coronaviruse/situation-reports/20200817-weekly-epi-update 1.pdf?sfvrsn=b6d49a76_4
WHO's COVID-19 Dashboard: https://covid19.who.int/
WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies:
ttps://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies
WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic : https://bit.ly/2Svds0r
WHO :Emergency Global Supply Chain System(COVID-19) catalogue:
ttps://www.who.int/publications/i/item/emergency-global-supply-chain-system-(covid-19)-catalogue
WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmun oassays :bit.1y/2IfOjVF
WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination :bit.ly/210wxWQ
WHO: interim guidance Operational considerations for COVID19 surveillance using GISRS: https://bit.ly/34APN5G
WHO: As COVID19 spread accelerates ,IHR Emergency Committee urges focus on measures that work : https://bit.ly/37ZI0I6 WHO: Thepush for aCOVID-19 vaccine :https://bit.ly/3mS3hAa
WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: bit.lv/3panKSM
WHO Living Guideline: The rapeutics and COVID-19: https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline
WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: https://www.who.int/publications/i/item/WHO-2019
COV-HCF assessment Products-2020.1
MHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector:
ttp://www.who.int/publications/i/item/evidence-to-recommendation-covid-19-mitigation-in-the-aviation-sector
WHO: Checklist to support schools re-opening and preparation for COVID -19 resurgences or similar public health crises:
ttps://www.who.int/publications/i/item/9789240017467
COVID-19 vaccine introduction and deployment costing tool: https://www.who.int/oublications/i/item/10665337553
WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19placebo-controlled vaccine trials and tria
nblinding:
tttps://www.who.int/publications/i/item/WHO-2019-nCoV-Policy Brief-EUD placebo-controlled vaccine trials-2020.1
WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19:
ttps://www.who.int/publications/i/item/WHO-2019-nCoV-Risk-based-international-travel-2020.1
WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19:
ttps://www.who.int/publications/i/item/WHO-2019-nCoV-Risk-based international travel-Assessment tool-2020.1
WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021:
ttps://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021
WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages:
ttps://www.who.int/publications/i/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages
WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access:
ttps://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access
WHO: Genomic sequencing of SARS -CoV-2: a guide to implementation for maximum impact on public health:
ttps://www.who.int/publications/i/item/9789240018440
WHO: Interim recommendations for use of the Pfizer -BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing:
ttps://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1
APORTANT CONTACTS

• The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAli5@health.gov.bh


• International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh



Total Number of Cases







1